2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma, lifting the company's shares more than 8% in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma ...

2seventy post spin - FDA sBLA Unlike bluebird, 2seventy has no new approvals to boost its forward potential. It does have an important supplemental application pending with a 12/16/2023 PDUFA date.

2seventy's Q3, 10-Q (the "10-Q") addresses its Regeneron (REGN) deal at several locations. It characterizes the deal as a key component of its strategic realignment so it can focus on the ...

2seventy bio Inc. stock TSVT rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it’s cutting 176 jobs or 40% of its work force and launching a ...

Revenue and impact to 2seventy: Based on an anticipated decline in Abecma sales in the third quarter, we believe full-year 2023 U.S. revenue for Abecma could be lower than the $470-$570 million ...

2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed ...

The market expects 2seventy bio, Inc. (TSVT) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus ...

2seventy bio, the cancer-focused spinout of bluebird bio, has paused a clinical trial in acute myeloid leukemia after a child died at Seattle Children's. Plus, other life sciences news you may ...

2seventy Bio reported that an acute myeloid leukemia patient treated with its experimental cell therapy has died, prompting research partner Seattle Children’s Research Institute to pause the ...